PTGX logo

PROTAGONIST THERAPEUTICS INC

PTGXNASDAQ
πŸ† #913 by market capEarnings Feb 23 Β· PostUS Equity
$121.50β€”
Last available close Β· quote unavailable
πŸ””
Track PTGX
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ–Ό 7.1%
14dβ–Ό 7.8%
30dβ–Ό 12.2%
ytdβ–² 39.2%
1yβ–² 42.2%
🏦Market Cap
$7.92B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-89.4%
Declining
πŸ“ŠGross Margin
99.7%
High
πŸ’΅FCF Margin
19.8%
Healthy
βš–οΈP/S Ratio
14.4x
Expensive
Otter Score
60
Fair

Trading Snapshot

Day Range
β€”
52-Week Range
$77.00 – $160.81
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
65.3M
Next Earnings
2027-02-23

Fundamentals Snapshot

Annual Revenue
$46M
Last Q Revenue
$274M
P/E Ratio
23.5
P/S Ratio
14.4x
EPS (TTM)
$5.16
Dividend Yield
0.00%
Dilution (1yr)
βˆ’4.3%
PTGX logo

PROTAGONIST THERAPEUTICS INC

PTGX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$46Mβ–Ό βˆ’89.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
97.3%β–Ό βˆ’2.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$158Mβ–Ό βˆ’162.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$56Mβ–Ό βˆ’69.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
63.6Mβ–Ό βˆ’4.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$118Mβ–² +$32M YoY
StockOtter Β· stockotter.space

About PROTAGONIST THERAPEUTICS INC

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
60/100
Analyst data unavailable.

Latest News & Updates

News unavailable.